TrialNature communications2022

CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.

M G Filippone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.